This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $275,000 to Brainstorm Therapeutics, Inc. will support the development and validation of a novel Parkinson's disease drug discovery platform using patient-derived midbrain organoids. The project aims to identify disease-modifying therapeutics that can halt, prevent, or reverse dopamine neuron degeneration associated with Parkinson's disease. The platform utilizes patient-derived stem cells, human-first drug discovery approaches, and advanced data analytics to overcome challenges in Parkinson's drug development and accelerate the discovery of transformative therapies. The award period is from July 15, 2024 to June 30, 2025.
Generated 1/28/25, 8:36 AM